(BHVN) Biohaven Pharmaceutical - Ratings and Ratios

Biohaven Ltd. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies across immunology, neuroscience, and oncology. The companys pipeline includes troriluzole, currently in Phase 3 trials for neurological and neuropsychiatric disorders; taldefgrobep alfa, also in Phase 3 for spinal muscular atrophy and obesity; BHV-7000, a Phase 3 candidate for epilepsy and major depressive disorder; and BHV-2100, targeting migraines and pain disorders in Phase 2. Additionally, BHV-1510 is in a Phase 1/2 trial for advanced or metastatic epithelial tumors, while BHV-8000 has completed Phase 1 for Alzheimers, Parkinsons, multiple sclerosis, and amyloid-related imaging abnormalities. Earlier-stage candidates include BHV-1300, BHV-1400, BHV-1100, BHV-1600, BHV-1310, BHV-1530, BHV-1500, and BHV-5500, targeting a range of conditions from Graves disease to urothelial cancer. The company leverages partnerships with Merus N.V., GeneQuantum Healthcare, Aimed Bio, Yale University, and others to advance its research and development efforts. Formerly known as Biohaven Research Ltd., the company rebranded as Biohaven Ltd. in September 2022 and is headquartered in New Haven, Connecticut.

Over the next three months, Biohavens stock (NYSE:BHVN) is expected to face volatility, with a potential test of the 19.1 support level. The stock is currently trading at 21.88, below its 50-day SMA of 27.00 and 200-day SMA of 38.55, indicating bearish momentum. The ATR of 2.17 suggests moderate price swings. On the fundamental side, the companys market cap of 2.388 billion USD and P/B ratio of 5.64 reflect its growth potential but also highlight valuation risks. The lack of P/E and RoE data underscores the companys focus on R&D over profitability. Positive clinical trial outcomes or strategic collaborations could act as catalysts, but near-term price action may remain constrained by technical resistance at 23.6 and 28.0 levels.